Abstract
The goal of the clinical management of hypoparathyroidism is to correct acute and chronic hypocalcemia. Treatment of acute hypoparathyroidism via intravenous infusion of Ca++ salts, is necessary only in symptomatic patients, or in asymptomatic patients in the setting of a rapid decrease in ionized Ca++ levels. The treatment cornerstones of chronic hypoparathyroidism are oral supplementation of calcium and/or active vitamin D, that can be associated with dietary restriction of sodium and phosphates, thiazide diuretics, and phosphate binders. Notably, PTH replacement is emerging as a innovative treatment of chronic hypoparathyroidism. rhPTH (1–84) has been shown to safely reduce calcium and vitamin D dosage, and increase serum calcium levels in hypoparathyroid patients. Therefore, rhPTH (1–84) appears to represent a new option in patients with chronic hypoparathyroidism “resistant” to conventional treatment. © 2018
Original language | English |
---|---|
Pages (from-to) | 955-964 |
Number of pages | 10 |
Journal | Best Practice and Research: Clinical Endocrinology and Metabolism |
Volume | 32 |
Issue number | 6 |
DOIs | |
Publication status | Published - 2018 |